NIPH Clinical Trials Search

Basic Information

Recruitment status
Health condition(s) or Problem(s) studied	Type 2 diabetes mellitus.
Date of first enrollment	10/06/2008
Target sample size	240
Countries of recruitment
Study type	Interventional
Intervention(s)	investigational material(s) Generic name etc : SYR-322 INN of investigational material : Therapeutic category code : 396 Antidiabetic agents Dosage and Administration for Investigational material : Oral

Outcome(s)

Primary Outcome	HbA1c change at the completion of treatment from baseline
Secondary Outcome

Key inclusion & exclusion criteria

Age minimum	Not applicable
Age maximum	Not applicable
Gender	Both
Include criteria	Key Criteria for inclusion: - The subject has been taking a stable dosage regimen of pioglitazone for at least 16 weeks prior to the initiation of the treatment period (Week 0) - The subject has an HbA1c value of 6.5% or more and below 10.0% at 14 weeks after the initiation of the screening period (Week -2) Key Criteria for exclusion: - The subject has taken any antidiabetic medications except pioglitazone within the last 16 weeks prior to the initiation of the treatment period (Week 0) - The subject with a history or symptoms of heart failure
Exclude criteria